Nicholas Hornstein, Assistant Professor of Medical Oncology at Northwell Health, shared a post on X:
“CheckMate 8HW is out and has ushered in a new era for dMMR mCRC.
However, any thoughts on using dual checkpoint inhibition for patients with advanced age or poor functional status?
Dual checkpoint in 90+? 80+? Start with single agent and rescue with CTLA4 if required? Age is just a number, but it can be informative…”